Phase I study of idarubicin dose escalation for remission induction therapy in acute myeloid leukemia

References

• Cassileth PA, Lynch E, Hines JD, et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood. 1992;79:1924–1930.
   PubMed Web of Science ®Google Scholar
• Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649–1656.
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361:1235–1248.
   PubMed Web of Science ®Google Scholar
• Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361:1249–1259.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015;125:3878–3885.
   PubMed Web of Science ®Google Scholar
• O'Donnell M, Tallman M, Abboud C. Acute myeloid leukemia induction treatment. NCCN Clin Pract Guidelines Oncol Acute Myeloid Leuk. 2015;12. 20th Annual Edition Version 1.
   Google Scholar
• Sessa C, Tschopp L, Fopp M, et al. Phase-I trial of 4-demethoxydaunorubicin in acute leukaemias. Invest New Drugs. 1985;3:357–359.
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009;101:708–720.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52:e56–e93.
   PubMed Web of Science ®Google Scholar
• Kolitz JE, George SL, Dodge RK, et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol. 2004;22:4290–4301.
   PubMed Web of Science ®Google Scholar
• Weiss MA, Drullinsky P, Maslak P, et al. A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia. Leukemia. 1998;12:865–868.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642–4649.
   PubMed Web of Science ®Google Scholar
• O'Donnell M, Tallman M, Abboud C, et al. Risk status based on validated cytogenetics and molecular abnormalities. NCCN Clin Pract Guidelines Oncol Acute Myeloid Leuk. 2015;20. 20th Annual Edition Version 1.
   Google Scholar
• Gieseler F, Clark M, Stiebeling K, et al. Induction of apoptosis by idarubicin: how important is the plasma peak? Int J Clin Pharmacol Ther. 2000;38:217–221.
   PubMed Web of Science ®Google Scholar
• Elbaek K, Ebbehoj E, Jakobsen A, et al. Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects. Clin Pharmacol Ther. 1989;45:627–634.
   PubMed Web of Science ®Google Scholar
• Tedeschi A, Montillo M, Strocchi E, et al. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Cancer Chemother Pharmacol. 2007;59:771–779.
   PubMed Web of Science ®Google Scholar
• Bengala C, Danesi R, Guarneri V, et al. High-dose consolidation chemotherapy with idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. Bone Marrow Transplant. 2003;31:275–280.
   PubMed Web of Science ®Google Scholar
• Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991;77:1666–1674.
   PubMed Web of Science ®Google Scholar
• Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol. 1992;10:1103–1111.
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Banks PL, Case DC. Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992;79:313–319.
   PubMed Web of Science ®Google Scholar
• Kerr DJ, Kaye SB. Aspects of cytotoxic drug penetration, with particular reference to anthracyclines. Cancer Chemother Pharmacol. 1987;19:1–5.
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA. 1989;86:695–698.
   PubMed Web of Science ®Google Scholar
• Reid JM, Pendergrass TW, Krailo MD, et al. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. Cancer Res. 1990;50:6525–6528.
   PubMed Web of Science ®Google Scholar
• Boogerd W, Tjahja IS, van de Sandt MM, et al. Penetration of idarubicin into malignant brain tumor tissue. J Neurooncol. 1999;44:65–69.
   PubMed Web of Science ®Google Scholar
• Kadia TM, Yang H, Ferrajoli A, et al. A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol. 2010;150:72–82.
   PubMed Web of Science ®Google Scholar
• Howard DS, Liesveld J, Phillips GL. II, et al. A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia. Leuk Res. 2013;37:1502–1508.
   PubMed Web of Science ®Google Scholar
• Tamura K. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan. Semin Hematol. 1996;33:2–11.
   PubMed Web of Science ®Google Scholar